Randomized double-blind placebo-controlled cosmetic trial of a topical first-in-class Neutraligand targeting the chemokine TARC/CCL17 in mild-to-moderate atopic dermatitis / Nelly Frossard in INTERNATIONAL JOURNAL OF COSMETIC SCIENCE, Vol. 46, N° 3 (06/2024)  

[article]  inINTERNATIONAL JOURNAL OF COSMETIC SCIENCE > Vol. 46, N° 3 (06/2024) . - p. 468-477 Titre : Randomized double-blind placebo-controlled cosmetic trial of a topical first-in-class Neutraligand targeting the chemokine TARC/CCL17 in mild-to-moderate atopic dermatitis Type de document : texte imprimé Auteurs : Nelly Frossard, Auteur ; Alexandra Coïc, Auteur ; Thibaut Saguet, Auteur ; Alain Coïc, Auteur ; Franck Himbert, Auteur ; Quoc Tuan Do, Auteur ; Jean-Luc Galzi, Auteur ; Carey Suehs, Auteur ; Gerald Guillaumet, Auteur ; Pascal Bonnet, Auteur ; Philippe Bernard, Auteur Année de publication : 2024 Article en page(s) : p. 468-477 Note générale : Bibliogr. Langues : Anglais (eng) Catégories : Barrière cutanée Dermo-cosmétologie Dermo-pharmacie Eczéma constitutionnel Étude randomisée Justification de l'allégation Ligands Peau -- Anatomie Peau -- Physiologie Peau -- Soins et hygiène Index. décimale : 668.5 Parfums et cosmétiques Résumé : - BACKGROUND : Atopic dermatitis has a marked economic impact and affects the quality of life. A cosmetic compound with an innovative strategy is proposed here as a small chemical neutraligand, GPN279 (previously identified as a theophylline derivative), that binds and potently neutralizes the TARC/CCL17 chemokine, activating the Th2 cell-expressed CCR4 receptor. - OBJECTIVE : Our objective was to evaluate the safety and activity of topically applied GPN279 in mild-to-moderate atopic dermatitis patients in a randomized, double-blind, placebo-controlled, parallel group trial. Such cosmetic active ingredient targeting dry skin with an atopic tendency would open a parallel strategy to the pharmaceutical approach, in particular for mild to moderate subjects, as an alternative to reduce the evolution towards severe forms of atopy. - METHODS : This 4-week trial included adults with mild-to-moderate atopic dermatitis, according to the SCORAD index. Patients were randomized into two groups treated by topical applications of either an emulsion containing 0.44% GPN279 in placebo on skin lesions or the placebo (4.56% glycerin). Clinical activity was evaluated with the SCORAD as the primary objective. As secondary objectives, POEM, erythema, skin moisturization, its barrier function (TEWL) and safety were evaluated. - RESULTS : Twenty-one patients in each group completed the study. SCORAD was significantly improved in the GPN279 group vs. placebo. GPN279 also significantly improved POEM, induced a rapid and significant decrease of erythema, and improved skin moisture. GPN279 and placebo were well tolerated throughout the study. - CONCLUSION : A cosmetic cream comprising the CCL17 neutraligand GPN279 improved the skin barrier and physiology criteria in patients with mild-to-moderate atopic dermatitis. Note de contenu : - METHODS : Study design - Patients - Treatments - Outcomes - Statistics - RESULTS : The study population - Primary objective : SCORAD - Secondary objectives : POEM - Erythema - Skin hydration - Safety DOI : https://doi.org/10.1111/ics.12948 En ligne : https://drive.google.com/file/d/1-YAIOelOQdWxMd_-dUoIEVDkva_5fKN8/view?usp=drive [...] Format de la ressource électronique : Pdf Permalink : https://e-campus.itech.fr/pmb/opac_css/index.php?lvl=notice_display&id=41347 [article]

Exemplaires

Code-barres	Cote	Support	Localisation	Section	Disponibilité
aucun exemplaire

---

1 (1 - 1 / 1)